Cargando…
Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts
PURPOSE: (1) To determine TweakR expression in human breast cancers (BC), (2) evaluate the antitumor effect of the anti-TweakR antibody PDL192, used alone or after chemotherapy-induced complete remission (CR), on patient-derived BC xenografts (PDX) and (3) define predictive markers of response. EXPE...
Autores principales: | de Plater, Ludmilla, Vincent-Salomon, Anne, Berger, Frédérique, Nicolas, André, Vacher, Sophie, Gravier, Eléonore, Thuleau, Aurélie, Karboul, Narjesse, Richardson, Marion, Elbaz, Clément, Marangoni, Elisabetta, Bièche, Ivan, Paoletti, Xavier, Roman-Roman, Sergio, Culp, Patricia A., Asselain, Bernard, Diéras, Véronique, Decaudin, Didier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222831/ https://www.ncbi.nlm.nih.gov/pubmed/25375638 http://dx.doi.org/10.1371/journal.pone.0104227 |
Ejemplares similares
-
Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb
por: Chao, Debra T., et al.
Publicado: (2012) -
Nuclear Factor κB is Required for Tumor Growth Inhibition Mediated by Enavatuzumab (PDL192), a Humanized Monoclonal Antibody to TweakR
por: Purcell, James W., et al.
Publicado: (2014) -
Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
por: Bieche, Ivan, et al.
Publicado: (2014) -
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers
por: Hatem, Rana, et al.
Publicado: (2016) -
Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization
por: Vallerand, David, et al.
Publicado: (2016)